Company overview
Parse Biosciences provides scalable single cell sequencing solutions using Evercode combinatorial barcoding technology, enabling analysis of up to 1 million cells from 384 samples in a single run without specialized instruments. Their portfolio includes Evercode Whole Transcriptome, TCR, BCR, Gene Select, and CRISPR Detect kits, supporting applications in immunology, drug discovery, and multi-omics research. The GigaLab service scales to billions of cells annually for large-scale projects.
Parse is listed in the NovaPharmaNews Supplier Hub as a Diagnostics & Testing partner serving United States & Americas. Core focus areas include single cell sequencing, evercode kits, combinatorial barcoding, crispr screening, immune profiling.
Industry categories: Diagnostics & Testing. These tags help R&D, manufacturing, and procurement teams discover vendors aligned with their pipeline stage and compliance requirements.
Structured facts
- Website
- https://www.parsebiosciences.com
- Categories
- Diagnostics & Testing
- Markets served
- United States & Americas
- Keywords
- single cell sequencing, evercode kits, combinatorial barcoding, crispr screening, immune profiling
Products & technologies
Markets served
Industry categories
Company timeline
- — Profile published on NovaPharmaNews
- — Profile last updated
Related suppliers in category
Frequently asked questions
- What is the maximum scale of single cell analysis with Parse Biosciences kits?
- Evercode WT Mega Kits support up to 384 samples and 1 million cells per run; GigaLab scales to 2.5 billion cells annually with demonstrations of 10 million cells in a single run.
- Does Parse Biosciences technology require specialized equipment?
- No, the instrument-free workflow uses standard lab equipment and combinatorial barcoding for scalable single cell RNA sequencing from fixed cells or nuclei.
- What applications are supported by Parse Biosciences products?
- Products enable whole transcriptome profiling, TCR/BCR immune repertoire analysis, CRISPR screening with gRNA detection, and Gene Select for targeted sequencing in immunology, drug target validation, and multi-omics studies.
Related editorial coverage
- $2M Gene Therapy Cures Need a Financing Model
- A Secure And Intelligent Drug Delivery Model Integrating Neural Networks With Blockchain
- AACR 2024: Daily Oncology Research Roundup
- AACR 2024: Oncology News & Key Takeaways - Day 1
- AACR 2024: Oncology Research Highlights - Day 1 Roundup
- AACR 2026: AI Pathology & Oncolytic Virus Spark Interest
Explore lab tools and QA/QC resources for R&D teams.
